Cancer
Lung cancer
肺癌
Tumours or cancer of the lung.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 251
- cities
- 73
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 40% of the world's English-language research papers on lung cancer, 2021–2025 (28% in 2016–2020), and 25% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
251 hospitals in 73 cities
Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 25 papers or 1 trial on lung cancer, or was a site in 16 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens lung cancer in that city. 63 more cities are in the menu below.
- 682 papers led
- 587 papers led
- 414 papers led
- 394 papers led
- 357 papers led
- 328 papers led
- 258 papers led
- 243 papers led
- 236 papers led
- 233 papers led
- 213 papers led
- 204 papers led
- 204 papers led
- 186 papers led
- 186 papers led
- 186 papers led
- 183 papers led
- 181 papers ledNo open trial led
- 176 papers ledNo open trial led
- 176 papers led
- 161 papers ledNo open trial led
- 161 papers led
- 156 papers ledNo open trial led
- 151 papers led
- 147 papers led
- 140 papers led
- 137 papers led
- 135 papers ledNo open trial led
- 127 papers led
- 125 papers led
- 124 papers ledNo open trial led
- 123 papers led
- 123 papers led
- 122 papers ledNo open trial led
- 120 papers led
- 115 papers led
- 112 papers led
- 111 papers ledNo open trial led
- 111 papers led
- 105 papers led
- 105 papers led
- 104 papers ledNo open trial led
- 103 papers ledNo open trial led
- 102 papers ledNo open trial led
- 102 papers led
- 99 papers led
- 92 papers led
- 89 papers led
- 88 papers led
- 88 papers led
- 83 papers led
- 83 papers led
- 82 papers ledNo open trial led
- 82 papers led
- 81 papers led
- 80 papers led
- 78 papers led
- 77 papers led
- 77 papers led
- 76 papers ledNo open trial led
- 75 papers ledNo open trial led
- 74 papers ledNo open trial led
- 74 papers ledNo open trial led
- 71 papers ledNo open trial led
- 69 papers led
- 69 papers led
- 69 papers led
- 68 papers led
- 68 papers led
- 68 papers led
- 67 papers led
- 66 papers led
- 66 papers ledNo open trial led
- 65 papers led
- 64 papers led
- 62 papers ledNo open trial led
- 62 papers led
- 61 papers ledNo open trial led
- 61 papers led
- 60 papers ledNo open trial led
- 60 papers led
- 59 papers ledNo open trial led
- 59 papers ledNo open trial led
- 59 papers ledNo open trial led
- 58 papers ledNo open trial led
- 57 papers led
- 56 papers led
- 55 papers ledNo open trial led
- 55 papers led
- 54 papers ledNo open trial led
- 53 papers led
- 53 papers ledNo open trial led
- 51 papers ledNo open trial led
- 51 papers ledNo open trial led
- 51 papers ledNo open trial led
- 51 papers led
- 50 papers ledNo open trial led
- 50 papers led
- 49 papers led
- 48 papers ledNo open trial led
- 47 papers ledNo open trial led
- 47 papers led
- 47 papers led
- 47 papers ledNo open trial led
- 46 papers ledNo open trial led
- 45 papers ledNo open trial led
- 45 papers led
- 45 papers ledNo open trial led
- 44 papers ledNo open trial led
- 43 papers ledNo open trial led
- 43 papers ledNo open trial led
- 42 papers ledNo open trial led
- 42 papers ledNo open trial led
- 41 papers ledNo open trial led
- 41 papers ledNo open trial led
- 41 papers led
- 41 papers ledNo open trial led
- 41 papers ledNo open trial led
- 41 papers ledNo open trial led
- 40 papers ledNo open trial led
- 40 papers ledNo open trial led
- 39 papers ledNo open trial led
- 39 papers ledNo open trial led
- 39 papers ledNo open trial led
- 38 papers ledNo open trial led
- 38 papers ledNo open trial led
- 37 papers ledNo open trial led
- 37 papers ledNo open trial led
- 37 papers ledNo open trial led
- 36 papers led
- 36 papers led
- 35 papers ledNo open trial led
- 34 papers ledNo open trial led
- 34 papers ledNo open trial led
- 34 papers ledNo open trial led
- 34 papers ledNo open trial led
- 33 papers ledNo open trial led
- 33 papers ledNo open trial led
- 33 papers led
- 33 papers ledNo open trial led
- 32 papers ledNo open trial led
- 32 papers ledNo open trial led
- 32 papers led
- 32 papers ledNo open trial led
- 32 papers led
- 32 papers ledNo open trial led
- 31 papers led
- 31 papers ledNo open trial led
- 31 papers ledNo open trial led
- 31 papers ledNo open trial led
- 31 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 29 papers ledNo open trial led
- 29 papers ledNo open trial led
- 28 papers ledNo open trial led
- 28 papers ledNo open trial led
- 28 papers led
- 28 papers ledNo open trial led
- 28 papers ledNo open trial led
- 28 papers led
- 27 papers ledNo open trial led
- 26 papers led
- 26 papers led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 23 papers ledNo open trial led
- 23 papers ledNo open trial led
- 23 papers ledNo open trial led
- 22 papers ledNo open trial led
- 22 papers ledNo open trial led
- 21 papers led
- 20 papers led
- 20 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers led
- 19 papers ledNo open trial led
- 19 papers led
- 19 papers led
- 18 papers ledNo open trial led
- 18 papers led
- 18 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 15 papers led
- 15 papers ledNo open trial led
- 14 papers ledNo open trial led
- 13 papers led
- 13 papers led
- 11 papers ledNo open trial led
- 10 papers led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers led
- 9 papers ledNo open trial led
- 9 papers led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers led
- 2 papers led
- 2 papers led
- 2 papers led
- 2 papers led
- 1 paper led
- 1 paper led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 59
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 945 papers led6 hospitals
- 773 papers led6 hospitals
- 731 papers led6 hospitals
- 653 papers led6 hospitals
- 637 papers led6 hospitals
- 636 papers led6 hospitals
- 573 papers led6 hospitals
- 558 papers led6 hospitals
- 500 papers led6 hospitals
- 476 papers led6 hospitals
- 464 papers led6 hospitals
- 458 papers led6 hospitals
- 416 papers led6 hospitals
- 375 papers led6 hospitals
- 374 papers led6 hospitals
- 370 papers led6 hospitals
- 369 papers led6 hospitals
- 345 papers led6 hospitals
- 307 papers led6 hospitals
- 306 papers led6 hospitals
- 302 papers led6 hospitals
- 299 papers led6 hospitals
- 264 papers led6 hospitals
- 258 papers led6 hospitals
- 243 papers led6 hospitals
- 231 papers led6 hospitals
- 224 papers led6 hospitals
- 212 papers led6 hospitals
- 207 papers led2 hospitals
- 206 papers led3 hospitals
- 192 papers led3 hospitals
- 181 papers led1 hospital
- 180 papers led6 hospitals
- 177 papers led3 hospitals
- 176 papers led1 hospital
- 176 papers led6 hospitals
- 175 papers led5 hospitals
- 171 papers led6 hospitals
- 166 papers led6 hospitals
- 140 papers led6 hospitals
- 132 papers led6 hospitals
- 130 papers led6 hospitals
- 129 papers led6 hospitals
- 122 papers led1 hospital
- 112 papers led2 hospitals
- 104 papers led6 hospitals
- 102 papers led1 hospital
- 92 papers led6 hospitals
- 75 papers led6 hospitals
- 67 papers led5 hospitals
- 63 papers led6 hospitals
- 59 papers led4 hospitals
- 56 papers led6 hospitals
- 55 papers led1 hospital
- 51 papers led3 hospitals
- 44 papers led2 hospitals
- 43 papers led2 hospitals
- 37 papers led1 hospital
- 21 papers led2 hospitals
open trials on lung cancer in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with at least one listed hospital as lead sponsor or site. 636 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT06951646
Age 18 years to 75 years (registered criteria)
Led by Second Xiangya Hospital; 12 listed hospitals as study sitesChangsha, Chongqing, Nanchang, Nanning, Shenyang, Taiyuan, Wuhan, Xinxiang
- RecruitingThe Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07039474
Age 18 years to 75 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingDurvalumab as Consolidation for Patients LS-SCLC
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07055581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesWuhan, Zhengzhou
- RecruitingA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase
- Phase 2/Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07063745
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Wuhan, Xiamen
- RecruitingZusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07076836
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07103395
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingHS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)
- Phase
- Phase 1
- Started
- 2026-08
- Posted
- Registry
- NCT07105176
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of DXC014 in Patients With Advanced Solid Tumors.
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07177937
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Qingdao
- RecruitingBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07195695
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07222566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingA Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07227025
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Harbin, Shanghai
- RecruitingSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07227298
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Shanghai, Taizhou, Wuhan
- RecruitingA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07227597
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangmen, Nanchang, Shanghai, Taizhou
- RecruitingA Phase II Study of SKB571 in Patients With Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07230405
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhengzhou
- RecruitingStudy of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07231445
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingTC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07246304
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingThis Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07249879
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingEffect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07251582
Age 18 years to 75 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07253142
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Guangzhou, Harbin, Hefei, Nanning, Shanghai, Wuhan, Xinxiang, Xuzhou
- RecruitingA Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07264816
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingA Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07269782
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07288177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingSKB500 Combinations in Patients With Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07296809
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07308106
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07309276
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThe Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07310056
Age 18 years to 85 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingFirmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07314216
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingAcupressure for Cough in Lung Cancer Survivors
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07315672
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingPostoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)
- Phase
- Phase 4
- Started
- 2026-01
- Posted
- Registry
- NCT07320105
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingNeoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07323056
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingA Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07325136
Age 18 years to Not stated (registered criteria)
Led by Shanghai East Hospital, Tongji UniversityShanghai
- RecruitingPhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07329322
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingFirst-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07332858
Age 18 years to 75 years (registered criteria)
Led by China-Japan Friendship HospitalBeijing
- RecruitingAndamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07336732
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingElectro-Acupuncture in Lung cancER : EALER Study
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07337096
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou
- RecruitingFirst in Human Study of SIM0610 in Solid Tumors
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07348211
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang
- RecruitingPulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07348965
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingNeoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07354061
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingA First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07354711
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07358676
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07361497
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shantou, Shenzhen, Suzhou, Taiyuan, Taizhou, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07361510
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shantou
- RecruitingZorifertinib With Osimertinib for NSCLC With Meningeal Progression
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07361705
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Shenyang, Taiyuan, Zhengzhou
- RecruitingA Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07367529
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan
- RecruitingIruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07374614
Age 18 years to Not stated (registered criteria)
Led by Peking University Shenzhen HospitalShenzhen
- RecruitingYSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2026-12
- Posted
- Registry
- NCT07390565
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingDouble-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
- Phase
- N/A
- Started
- 2026-02
- Posted
- Registry
- NCT07398599
Age 18 years to 99 years (registered criteria)
Led by Second Affiliated Hospital of Nanchang UniversityNanchang
- RecruitingComparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07398937
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingIBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07408635
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingEfficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07410975
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingA Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07412262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Wuhan
- RecruitingA Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07413042
Age 18 years to 80 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingPHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07416058
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07416474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai
- RecruitingA Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07416695
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07431827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Urumqi, Wuhan
- RecruitingA Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07434518
Age 18 years to 100 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingStudy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07435038
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingA Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07444437
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Zhengzhou
- RecruitingAn Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07452003
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingThe Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
- Phase
- Early phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07459283
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuxi
- RecruitingA Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07459751
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingDual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07467863
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingPhase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07472478
Age 18 years to 80 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07472517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07476287
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Retrospective Real-World Study Based on RATIONALE-307
- Phase
- Not given
- Started
- 2026-02
- Posted
- Registry
- NCT07478809
Age not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingDual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07480213
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingBevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07481786
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesChongqing, Guangzhou
- RecruitingBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07486817
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingCadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07487883
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07489066
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingFulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07492342
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou
- RecruitingA Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07502300
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou
- RecruitingLarge Language Models Assist in Tumor MDT
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07504367
Age 25 years to 33 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingHippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07505173
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingMDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07509333
Age 60 years to 90 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingElectroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07515027
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingJS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07518160
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDownstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07528066
Age not stated (registered criteria)
Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin
- RecruitingMicrowave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07528274
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07541170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Shenzhen, Suzhou, Taizhou, Tianjin
- RecruitingRATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07541521
Age not stated (registered criteria)
Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin
- RecruitingA Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07548060
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingVebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07549061
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingSub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07552467
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07554339
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen
- RecruitingComparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07554846
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Recruiting18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07557225
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07559786
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
- Phase
- Phase 1/Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07559929
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Phase II Study of GC101 in NSCLC
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07560111
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingFeasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07561567
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingIMP3-saRNA Vaccine in Advanced NSCLC
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07561723
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07562581
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSeptum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07564557
Age 18 years to 80 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingEstablishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07565532
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07566052
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanning, Suzhou, Taiyuan
- RecruitingLow-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07583550
Age 18 years to 75 years (registered criteria)
Led by Jiangmen Central HospitalJiangmen
- RecruitingA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07586202
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin
- RecruitingStudy of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07589205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingAMT-116 in Combination With AK112 in Patients With Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07590531
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou
- RecruitingSerplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07596121
Age 65 years to Not stated (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingHypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07609121
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07610798
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingSub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07612722
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07622186
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shenyang, Taiyuan, Tianjin, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingFirmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07622706
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07623356
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingAssociation Between Screening Behaviors and Lung Cancer Spectrum
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07626177
Age not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07637448
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study of HDM2020 in Patients With Advanced Sq-NSCLC
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07638891
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07640789
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan
- RecruitingDual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07641023
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
- Phase
- Phase 2/Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07642024
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai
- RecruitingPHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07645222
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07654400
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingVebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07655622
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Nanchang UniversityNanchang
- RecruitingSCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07662395
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingCharacterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07668037
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07668752
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07672223
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai
- RecruitingPrecision Navigation to Improve Community Cancer Screening Participation
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07676383
Age 45 years to 74 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingDLL3-Targeted PET/CT in Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07677787
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingLabel-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07681245
Age 18 years to 90 years (registered criteria)
Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingSafety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
- Phase
- Early phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07689643
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingEfficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07696832
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingSKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07697586
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Phase
- Phase 1/Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07707895
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesNanning, Shanghai
- RecruitingBefotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07709585
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
- Phase
- Phase 2/Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07739186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou
- RecruitingA Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
- Phase
- Phase 2/Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07739199
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Wuhan
- RecruitingA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07739758
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shenyang
- RecruitingA Study of DS-3939a in Participants With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07739966
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou
- RecruitingAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07744256
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingAmivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07744529
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingMetronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
- Phase
- Phase 4
- Started
- 2026-07
- Posted
- Registry
- NCT07744698
Age 18 years to 75 years (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- RecruitingAnalgesic Effects of Retro-superior Costotransverse Ligament Space Block for Video-assisted Thoracoscopic Surgery
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07745881
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingEffect of Modified Arm Positioning on Shoulder Pain After Thoracoscopic Lobectomy
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07746323
Age 18 years to Not stated (registered criteria)
Led by Child Health HospitalChengdu
- RecruitingctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07751536
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei
- RecruitingOral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
- Phase
- Phase 4
- Started
- 2026-06
- Posted
- Registry
- NCT07754812
Age 70 years to Not stated (registered criteria)
Led by Shanghai Pulmonary Hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai
- RecruitingNK Cells Plus ICI for SCLC Maintenance
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07759856
Age 18 years to Not stated (registered criteria)
Led by Tianjin First Central HospitalTianjin
- Recruiting68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07760012
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingAcupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
- Phase
- N/A
- Started
- 2026-07
- Posted
- Registry
- NCT07768124
Age 18 years to 75 years (registered criteria)
Led by Affiliated Yongchuan Hospital of Chongqing Medical UniversityChongqing
- RecruitingPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07778316
Age 18 years to 99 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingStudy on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07783971
Age 30 years to 80 years (registered criteria)
Led by Army Hospital
- RecruitingA Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07798947
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan
- RecruitingA Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07802821
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingReal World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07806604
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingOlive Oil Before Lung Cancer Surgery to Prevent Chylothorax
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07807696
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingWireless Wearable Home Prehabilitation for Older Adults With NSCLC
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07809763
Age 65 years to 85 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingSIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07823855
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07824882
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingA Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)
- Phase
- Phase 1
- Started
- 2026-09
- Posted
- Registry
- NCT07830342
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingCAIX-targeted PET/CT in Solid Tumors
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07833085
Age 18 years to Not stated (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingA Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07843940
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Harbin, Shanghai
- RecruitingClinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07848243
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingMulticenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07855965
Age 18 years to 80 years (registered criteria)
Led by West China Hospital; 3 listed hospitals as study sitesChengdu, Luzhou, Nanchong
- RecruitingAn Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07863167
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingNeoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07863999
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary Hospital; 4 listed hospitals as study sitesShanghai
- RecruitingEffectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07874581
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07880106
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingReal-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07880353
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingPropranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07886047
Age 18 years to 75 years (registered criteria)
Led by Second Xiangya Hospital; 3 listed hospitals as study sitesChangsha
- RecruitingPropranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07886229
Age 18 years to 75 years (registered criteria)
Led by Second Xiangya Hospital; 3 listed hospitals as study sitesChangsha
- RecruitingMRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07894458
Age 18 years to 85 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingExploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain Injury
- Phase
- Not given
- Started
- 2026-06
- Posted
- Registry
- NCT07905937
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang
- RecruitingePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07912190
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Recruiting68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07914764
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingPragmatic AI-Assisted Lung Cancer Translational Study
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07941128
Age 18 years to Not stated (registered criteria)
Led by Sir Run Run Shaw Hospital; 1 listed hospital as study siteHangzhou, Zhengzhou
- RecruitingNectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT05321316
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingThe Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT05798845
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
- Phase
- Phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT06232083
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingIntrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT06296745
Age 18 years to 75 years (registered criteria)
Led by Affiliated Huizhou Hospital of Guangzhou Medical UniversityHuizhou
- RecruitingPhase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06348797
Age 18 years to 70 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06568939
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Harbin, Linyi, Nanchang, Nanning, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06674252
Age 65 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingSleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT06687408
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou, Shanghai
- RecruitingSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06712316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou
- RecruitingSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06712355
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingThe Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06738160
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06754930
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06758401
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingPost-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06758700
Age 18 years to 75 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingAssessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06768307
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06769295
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingPhase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06769971
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingAssociation Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06771960
Age 18 years to 80 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06772623
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Nanchang, Nanjing, Shanghai, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingPhase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06773507
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06775743
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06776588
Age 18 years to 75 years (registered criteria)
- RecruitingSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06780098
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Zhengzhou
- RecruitingA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06780137
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanjing, Shanghai
- RecruitingA Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06792552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang
- RecruitingA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06793215
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan
- RecruitingStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06801834
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingClinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06809764
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou
- RecruitingBiomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT06818149
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06829459
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingTislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06838208
Age 18 years to Not stated (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- RecruitingA Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06839105
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan
- RecruitingImmunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06840704
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha
- RecruitingDREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT06846762
Age not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06848699
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Chongqing, Jinan
- RecruitingImmunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06849167
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingSecond-line Immunotherapy for ES-SCLC
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06853678
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT06855771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Linyi, Nanchang, Nanning, Taizhou, Xiamen
- RecruitingA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06858813
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingThe Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06861543
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingReal World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06862869
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi
- RecruitingPerioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06864624
Age 18 years to Not stated (registered criteria)
Led by Tangdu Hospital; 2 listed hospitals as study sitesChangsha, Xi'an, Yinchuan
- RecruitingA Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT06868485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Shanghai, Tianjin, Wuhan
- RecruitingEvaluation of JSKN016 Combination Therapy in Subjects With NSCLC
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06868732
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingPrediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06869239
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06875310
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
- RecruitingLow-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06877299
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06890598
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an
- RecruitingA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06892548
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Xi'an, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yichang, Zhengzhou
- RecruitingStudy of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06895031
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingRandomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT06896422
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingPerioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06897046
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06899126
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingA Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06901817
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSafety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06902350
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changchun
- RecruitingAnti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06903117
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06903377
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06907615
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT06914427
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingPostoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC(ARMOR2501)
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06924398
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAcupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06926140
Age 18 years to 75 years (registered criteria)
Led by Guang'anmen Hospital; 1 listed hospital as study siteBeijing, Hefei
- RecruitingNeoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06926790
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingPhase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06927986
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06928389
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingTrilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06929936
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingA Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06930794
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingLiquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06930807
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Recruiting18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06937112
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingCryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06939127
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingSleep Disorders and Tumor Immune Microenvironment
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT06941948
Age 18 years to 70 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingAn Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06942143
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingStudy of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06943235
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAK129 Combination Therapy for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06943820
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang
- RecruitingA Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT06946927
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingA Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06947694
Age 18 years to 75 years (registered criteria)
Led by Xinqiao Hospital, Army Medical UniversityChongqing
- RecruitingA Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06951464
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingStudy on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06953843
Age 18 years to 75 years (registered criteria)
Led by Xinqiao Hospital, Army Medical UniversityChongqing
- RecruitingA Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06954246
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06955988
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingOrganoid-guided Personalized Treatment of Pleural Effusion
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06959173
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06962865
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingBovine Reinforcement in Stomach, Colorectal and Lung Operation
- Phase
- Phase 3
- Started
- 2025-05
- Posted
- Registry
- NCT06968221
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingTransbronchial MWA for Pulmonary Tumors
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT06969014
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06969612
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingPROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06977074
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNeoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06987734
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingTrilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT06992739
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingA Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07003321
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingRadical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT07003490
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07005102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Wuhan
- RecruitingReal-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07008287
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingOmitting CTV for Primary Tumor in LS-SCLC
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07008716
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07010263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi
- RecruitingConsolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07014202
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Study of SKB518 in Patients With Lung Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07019675
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenzhen, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xiangyang, Zhengzhou
- RecruitingTubeless Anesthesia in Preventing Lung Complications in Patients Undergoing Surgery for Early-Stage Lung Cancer
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT07024433
Age 18 years to 70 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingA Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT07026669
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingElectroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07034326
Age 18 years to 80 years (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingA Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07034391
Age 18 years to 75 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- RecruitingZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07038096
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingToripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT07039656
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingHypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07052669
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteChongqing, Guangzhou
- RecruitingA Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07056556
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingMultiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT07057102
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07058519
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingSpatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07058948
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteBeijing, Tianjin
- RecruitingPredicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07059923
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingSintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07061535
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 4 listed hospitals as study sitesChangsha, Hangzhou, Jinan
- RecruitingPhase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07063329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou
- RecruitingStaging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07066813
Age not stated (registered criteria)
Led by Second Xiangya HospitalChangsha
- RecruitingDZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07070440
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy of GV20-0251 in Participants With Solid Tumor Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07070518
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingIntestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07071103
Age 18 years to 80 years (registered criteria)
Led by Shantou University Medical College hospitalsShantou
- RecruitingStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07079475
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin
- RecruitingA Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07082179
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Cancer HospitalNanjing
- RecruitingElectroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07086300
Age 65 years to 100 years (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingCombination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07086456
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingPhase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07087223
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 7 listed hospitals as study sitesBeijing, Dalian, Shijiazhuang, Tianjin
- RecruitingTislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07089199
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07090499
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingA Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07091305
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingSDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07096882
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Phase
- Phase 2/Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07100080
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesFuzhou, Taiyuan, Wuhan
- RecruitingA Study of GV20-0251 in Advanced or Refractory Solid Tumors
- Phase
- Phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07106827
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingPerioperative Immunotherapy for Resectable Limited-Stage SCLC
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT07109401
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07109531
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingGolidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07110103
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 1 listed hospital as study siteBeijing, Chongqing
- RecruitingA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07111520
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou
- RecruitingSunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT07117890
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07120282
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingAdaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07120698
Age 28 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingIBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07122687
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang
- RecruitingSFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
- Phase
- Phase 2/Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT07131319
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Nanchang UniversityNanchang
- RecruitingThoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07134660
Age 18 years to 80 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingSleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07135856
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingThe Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07138755
Age 18 years to 75 years (registered criteria)
Led by Third Xiangya Hospital; 1 listed hospital as study siteChangsha
- RecruitingAdebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07141264
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingA Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07143045
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07144280
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingNanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07150663
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07154706
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07155174
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07155187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Nanchang, Shanghai, Urumqi
- RecruitingA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07164170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- RecruitingEfficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT07166003
Age 18 years to 79 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingHC010 in First-line PD-L1 Positive Advanced NSCLC Patients
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07169552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07169994
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang
- RecruitingA Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07171606
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07174908
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingPhase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07175220
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07178795
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07181473
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingSequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07181499
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingStudy Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07189455
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07190248
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07193641
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingTo Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07195084
Age 18 years to Not stated (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- RecruitingIBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07198841
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Foshan, Guangzhou, Nanchang, Nanning, Shijiazhuang
- RecruitingStudy on the Mechanism of Acquired Resistance of Entrectinib
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT07199959
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of YL202 in Patients With Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07202364
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
- RecruitingA Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07206498
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesFuzhou, Shanghai, Tianjin
- RecruitingA Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07208773
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingIntraoperative Paravertebral Block and Postoperative Complications
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT07211529
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07217301
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou
- RecruitingA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07218146
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07226999
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingA Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07229599
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07229729
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2025-11
- Posted
- Registry
- NCT07232420
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingSafety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules
- Phase
- N/A
- Started
- 2025-11
- Posted
- Registry
- NCT07232433
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07232849
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingElectroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
- Phase
- N/A
- Started
- 2025-11
- Posted
- Registry
- NCT07239661
Age 18 years to Not stated (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingA Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07241767
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingSynthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07243873
Age 18 years to 85 years (registered criteria)
Led by Shanghai Pulmonary Hospital; 3 listed hospitals as study sitesNanchang, Shanghai, Zunyi
- RecruitingClinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT07244016
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Study of Ivonescimab in First-Line ES-SCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07245446
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai, Xi'an
- RecruitingA Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-10
- Posted
- Registry
- NCT07250386
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07252739
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Nanchang, Nanjing, Shanghai
- RecruitingApplication of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT07257458
Age 18 years to 85 years (registered criteria)
Led by Beijing Haidian HospitalBeijing
- RecruitingApplication Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07257471
Age 18 years to 85 years (registered criteria)
Led by Beijing Haidian HospitalBeijing
- RecruitingVSV-02 Compassionate Use in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07260591
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xinxiang Medical UniversityXinxiang
- RecruitingA Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07274852
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingTo Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT07291921
Age 18 years to 85 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingExploratory Trial of Navigational Bronchoscopy-Guided Cryoablation in Lung Cancer Treatment
- Phase
- N/A
- Started
- 2025-11
- Posted
- Registry
- NCT07301411
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingFurmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07304739
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingNeoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07309952
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingOsimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT07322783
Age 18 years to 80 years (registered criteria)
Led by Qingdao Central HospitalQingdao
- RecruitingTALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07330037
Age 17 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingWAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07330050
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingQL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07330596
Age 18 years to 75 years (registered criteria)
- Recruiting68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07331532
Age 18 years to 80 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingFunctional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm Clinical Study
- Phase
- N/A
- Started
- 2025-10
- Posted
- Registry
- NCT07339644
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Chongqing Medical UniversityChongqing
- RecruitingMechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07359040
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07361237
Age 18 years to 75 years (registered criteria)
Led by Shanghai East Hospital, Tongji UniversityShanghai
- RecruitingA Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07362459
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
- Phase
- Phase 1/Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07362940
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Jinan, Xiamen, Zhengzhou
- RecruitingAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07371663
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou
- RecruitingA Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07373964
Age 18 years to 75 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- RecruitingA ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07375316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Shantou, Shenzhen
- RecruitingA Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07376707
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
- Phase
- Phase 1
- Started
- 2025-10
- Posted
- Registry
- NCT07381829
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingPrediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07388771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Wuhan
- RecruitingTislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07425795
Age 18 years to 75 years (registered criteria)
Led by Chongqing University Cancer HospitalChongqing
- RecruitingAnlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07443397
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingFAP-targeted PET/NIR in Lung Malignant Tumors
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07498933
Age 18 years to 70 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Recruiting68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07508852
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingFL-261 Imaging for Cancer Diagnosis and Staging
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07510321
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingPhase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07534033
Age 18 years to 80 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingExploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07559097
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingRomiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07586826
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingMultimodal AI-Guided Recovery Management After Lung Cancer Surgery
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT07588737
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingStudy on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07610616
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingThe Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07617246
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEvaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07626736
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingEffectiveness of Perioperative Percutaneous Acupuncture on Postoperative Sleep Disturbances and Chronic Pain in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT07662733
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingTargeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07742332
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingAdjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT07748325
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingPD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
- Phase
- Not given
- Started
- 2025-10
- Posted
- Registry
- NCT07775820
Age 18 years to Not stated (registered criteria)
Led by Nanfang Hospital; 4 listed hospitals as study sitesGuangzhou, Nanchang, Shenzhen, Wenzhou
- RecruitingStation 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLC
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07801430
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07815223
Age 18 years to 75 years (registered criteria)
Led by Yantai Yuhuangding HospitalYantai
- RecruitingMultimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT07820423
Age 18 years to Not stated (registered criteria)
Led by Second Xiangya HospitalChangsha
- RecruitingAdjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07837739
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingLongitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT07895277
Age 35 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingExploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT07947043
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingPembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT05266846
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingCarbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT05613452
Age 18 years to 80 years (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingFirst Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT05745350
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT05956587
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Luoyang, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingPropranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-11
- Posted
- Registry
- NCT05979818
Age 18 years to 75 years (registered criteria)
Led by Second Xiangya HospitalChangsha
- RecruitingOmitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
- Phase
- N/A
- Started
- 2024-02
- Posted
- Registry
- NCT06020430
Age 18 years to 75 years (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingSingle-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06032052
Age 65 years to Not stated (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingPrimary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
- Phase
- N/A
- Started
- 2024-03
- Posted
- Registry
- NCT06037733
Age 18 years to 75 years (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingObservation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery
- Phase
- Not given
- Started
- 2024-03
- Posted
- Registry
- NCT06109454
Age 18 years to 75 years (registered criteria)
Led by Liaoning Cancer Hospital & InstituteShenyang
- RecruitingPhase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06121505
Age 18 years to 75 years (registered criteria)
Led by West China Hospital; 4 listed hospitals as study sitesChengdu, Chongqing, Nanchong, Wuhan
- RecruitingToripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06127303
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest Hospital; 2 listed hospitals as study sitesShanghai
- RecruitingStudy of LY01610 in Patients With Recurrent Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06128837
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06172478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingA Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06179069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingSunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure:Phase I/II
- Phase
- Phase 1/Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06195189
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingGPC3/Mesothelin-CAR-γδT Cells Against Cancers
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06196294
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingMRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
- Phase
- Not given
- Started
- 2024-02
- Posted
- Registry
- NCT06198868
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Cancer HospitalNanjing
- RecruitingA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06203210
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingA Study of HLX42 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2024-03
- Posted
- Registry
- NCT06210815
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingShort-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients
- Phase
- N/A
- Started
- 2024-01
- Posted
- Registry
- NCT06215326
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingSafety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06217757
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingWBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
- Phase
- Phase 1/Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06243003
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingThe Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
- Phase
- N/A
- Started
- 2024-03
- Posted
- Registry
- NCT06244264
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingNeoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06256237
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingIrinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT06258642
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingNeoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06269211
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 1 listed hospital as study siteGuangzhou, Shanghai
- RecruitingDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06283719
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSerplulimab Combined With CCRT for LS-SCLC.
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06295926
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingIntra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT06304441
Age 18 years to 75 years (registered criteria)
Led by Third People's Hospital, Guangzhou Medical UniversityGuangzhou
- RecruitingA Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06306456
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Hefei, Nanjing, Shanghai, Taizhou, Zhengzhou
- RecruitingCarbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06311981
Age 75 years to Not stated (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase
- Phase 3
- Started
- 2024-04
- Posted
- Registry
- NCT06312137
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Taizhou, Wuhan, Xi'an, Zhengzhou
- RecruitingSurvival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06338683
Age 18 years to 80 years (registered criteria)
Led by Qinghai Red Cross HospitalXining
- RecruitingA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06345729
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou
- RecruitingSunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06348927
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingTo Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06352008
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingSunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06355609
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingReal World Study of Lolatinib for Advanced ALK+ NSCLC Patients
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06361589
Age 18 years to Not stated (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- RecruitingOsimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06363734
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of GC203 TIL in Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06375187
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingRadiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06379087
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingNeoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06383728
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06388031
Age 18 years to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06403735
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHarbin, Kunming, Nanchang, Shanghai
- RecruitingJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06416410
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou
- RecruitingA Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06417008
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Tianjin
- RecruitingA Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06421298
Age 18 years to 75 years (registered criteria)
Led by Beijing Chest HospitalBeijing
- RecruitingPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Phase
- Phase 3
- Started
- 2024-06
- Posted
- Registry
- NCT06422143
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Study of FZ-AD005 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06424665
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Hangzhou, Shanghai
- RecruitingA Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06424899
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06426511
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingPD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06429696
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06430437
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSafety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06431685
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06437509
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
- Phase
- Phase 3
- Started
- 2024-09
- Posted
- Registry
- NCT06437977
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06440057
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06440954
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingEfficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06445881
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06452277
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen
- RecruitingResearch on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients.
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06458894
Age 60 years to 99 years (registered criteria)
Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou
- RecruitingA Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
- Phase
- Phase 1
- Started
- 2024-06
- Posted
- Registry
- NCT06461156
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingA Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06467500
Age 18 years to 75 years (registered criteria)
Led by Yichang Central People's HospitalYichang
- RecruitingAdebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06467617
Age 18 years to 75 years (registered criteria)
Led by Beijing Chest HospitalBeijing
- RecruitingStudy on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
- Phase
- Phase 4
- Started
- 2024-03
- Posted
- Registry
- NCT06467786
Age 18 years to Not stated (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingA Phase Ib Study of GC101 in NSCLC
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06473961
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingAdebrelimab + Apatinib in SCLC Maintenance Therapy
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06475209
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06475300
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingInterventional Software for Multi-immunotherapy of Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2024-04
- Posted
- Registry
- NCT06478108
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingAdebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06480864
Age 18 years to Not stated (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- RecruitingA Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06483282
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingImproving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
- Phase
- N/A
- Started
- 2024-03
- Posted
- Registry
- NCT06483295
Age 18 years to 80 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingCheckpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06483347
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingTGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06484816
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingNeoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06485544
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingNeoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06492421
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingLurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
- Phase
- Phase 3
- Started
- 2024-09
- Posted
- Registry
- NCT06496048
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- RecruitingA Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06496490
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi
- RecruitingMaintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06497530
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingDecoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach(Radiogenomics-Lung)
- Phase
- Not given
- Started
- 2024-07
- Posted
- Registry
- NCT06500312
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingCranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06501391
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingTransthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer
- Phase
- N/A
- Started
- 2024-01
- Posted
- Registry
- NCT06503744
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06505824
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06512051
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06514027
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingChemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
- Phase
- Not given
- Started
- 2024-04
- Posted
- Registry
- NCT06514118
Age 18 years to 80 years (registered criteria)
Led by Qingdao Central HospitalQingdao
- RecruitingBefotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06517953
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingDifferentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
- Phase
- Not given
- Started
- 2024-06
- Posted
- Registry
- NCT06518655
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Foshan, Guangzhou, Shanghai, Wuhan
- RecruitingStereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-09
- Posted
- Registry
- NCT06523673
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingHypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06527898
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
- Phase
- Not given
- Started
- 2024-06
- Posted
- Registry
- NCT06528418
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingAdjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06528847
Age 18 years to 74 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingNeoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06532591
Age 18 years to 70 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- RecruitingMilaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06534762
Age 18 years to 65 years (registered criteria)
Led by Zhejiang Provincial People's HospitalHangzhou
- RecruitingTislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06536868
Age 18 years to 80 years (registered criteria)
Led by Second Hospital of Shanxi Medical University; 1 listed hospital as study siteTaiyuan
- RecruitingElimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06542159
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingPrimary Tumor Resection for M1a Stage Lung Cancer
- Phase
- Not given
- Started
- 2024-04
- Posted
- Registry
- NCT06547710
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEffect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT06548711
Age 18 years to 80 years (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- RecruitingOlanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06554613
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Nanchang UniversityNanchang
- RecruitingA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Phase
- Phase 3
- Started
- 2024-10
- Posted
- Registry
- NCT06561386
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang
- RecruitingBefotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
- Phase
- Phase 4
- Started
- 2024-05
- Posted
- Registry
- NCT06561620
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAdebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06562920
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06563999
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06564324
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingStudy of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06567015
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin
- RecruitingTransthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
- Phase
- N/A
- Started
- 2024-09
- Posted
- Registry
- NCT06572540
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Shanghai, Zhengzhou
- RecruitingVebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06574347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06581419
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingElimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06582940
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSafety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06596915
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSubcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06598306
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai
- RecruitingStereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
- Phase
- Phase 3
- Started
- 2024-10
- Posted
- Registry
- NCT06598527
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingEfficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06607796
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingMulticenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06610734
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06612840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06613009
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Fuzhou, Hangzhou, Hefei, Jinan, Nanchang, Zhengzhou
- RecruitingA Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06617416
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan
- RecruitingPhase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06621563
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingThe Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
- Phase
- Not given
- Started
- 2024-07
- Posted
- Registry
- NCT06623487
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Phase 2 Clinical Study of ABSK061 and ABSK043
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06632262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Jinan, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingAI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06632886
Age 18 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingSegmentectomy for Solid-dominant Lung Cancer
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06634966
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSelective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
- Phase
- N/A
- Started
- 2024-05
- Posted
- Registry
- NCT06634979
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase I Study of CFT8919 in Patients With Advanced NSCLC
- Phase
- Phase 1
- Started
- 2024-11
- Posted
- Registry
- NCT06641609
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingPartial Pressure of Oxygen Control Method in Identification of Intersegmental Plane
- Phase
- N/A
- Started
- 2024-05
- Posted
- Registry
- NCT06644066
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingAblation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT06644430
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingRadiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06648317
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingHigh-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06652048
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingPerioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06659042
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingIntrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06663306
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06667908
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06668103
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangchun, Harbin, Shanghai, Wuhan
- RecruitingFurmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06674343
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingArtificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06684418
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingThe Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06692972
Age 18 years to Not stated (registered criteria)
Led by China-Japan Friendship Hospital; 1 listed hospital as study siteBeijing, Wuhan
- RecruitingEfficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06698965
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingMulti-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06699979
Age 18 years to Not stated (registered criteria)
Led by Second Xiangya HospitalChangsha
- RecruitingCadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06702826
Age 18 years to 75 years (registered criteria)
Led by Xiangya HospitalChangsha
- RecruitingLow Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06714708
Age 18 years to Not stated (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- RecruitingChemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06718309
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingA Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
- Phase
- Not given
- Started
- 2024-09
- Posted
- Registry
- NCT06718972
Age not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingConcurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06719700
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingEfficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06728852
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingElimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06730295
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNeoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06734182
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingNeoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06734702
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingClinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT06739031
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingApplication of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT06742021
Age 18 years to 75 years (registered criteria)
Led by Yunnan Cancer HospitalKunming
- RecruitingLymph Node Pathologic Grading Strategy
- Phase
- Not given
- Started
- 2024-04
- Posted
- Registry
- NCT06745830
Age not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingLiposomal Irinotecan and Apatinib in ES-SCLC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06749691
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingDisitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06749860
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingAn Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06749886
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingNeoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06755684
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Recruiting68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06756217
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06768151
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingA Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06775275
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSpatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06775678
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study on the Efficacy of Atezolizumab Combined with Chemotherapy
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06780826
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingAssessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
- Phase
- Phase 1
- Started
- 2024-06
- Posted
- Registry
- NCT06813365
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Application of PET Imaging Targeting MSLN in Malignant Tumors
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT06843629
Age 18 years to 65 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingEstablishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06843707
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingTrop2-targeted immunoPET Imaging of Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2024-12
- Posted
- Registry
- NCT06851663
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingPhase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06863506
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of JMT203 in Patients With Cancer Cachexia
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06868849
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingA Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06873555
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBengbu, Changsha
- RecruitingStudy of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06911606
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingSafety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06926179
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 2 listed hospitals as study sitesBeijing, Kunming
- RecruitingFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06956001
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan
- RecruitingA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
- Phase
- Phase 3
- Started
- 2024-09
- Posted
- Registry
- NCT06970639
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingThe Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06975384
Age 18 years to Not stated (registered criteria)
Led by Second Xiangya HospitalChangsha
- RecruitingThe Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
- Phase
- N/A
- Started
- 2024-07
- Posted
- Registry
- NCT06988579
Age 40 years to 74 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingEarly Intervention Strategies for Lung Cancer
- Phase
- N/A
- Started
- 2024-06
- Posted
- Registry
- NCT06988943
Age 40 years to 74 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingD-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT07016126
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingClinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT07026110
Age 18 years to 80 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingTislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer:A Prospective, Single-Arm, Phase II Study
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT07085182
Age 18 years to 75 years (registered criteria)
Led by Zibo Municipal HospitalZibo
- RecruitingSymptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes
- Phase
- Not given
- Started
- 2024-06
- Posted
- Registry
- NCT07131670
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingValidation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT07239063
Age not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingNoninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT07399210
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingCarbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT07433283
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou
- RecruitingStudy of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT07439991
Age 18 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingAn Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT07444281
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT07463300
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 7 listed hospitals as study sitesChengdu, Hangzhou, Shenyang, Wuhan, Yangzhou
- RecruitingClinical Study of a New Treatment Model for Elderly Lung Cancer Patients
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT07632664
Age 65 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingShared Decision Making in Patients With Lung Cancer
- Phase
- Not given
- Started
- 2023-02
- Posted
- Registry
- NCT05191485
Age 18 years to Not stated (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- RecruitingSugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
- Phase
- Phase 2/Phase 3
- Started
- 2023-07
- Posted
- Registry
- NCT05623267
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSegmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
- Phase
- Phase 3
- Started
- 2023-02
- Posted
- Registry
- NCT05717803
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEfficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
- Phase
- N/A
- Started
- 2023-08
- Posted
- Registry
- NCT05754203
Age 18 years to 75 years (registered criteria)
Led by Xinqiao Hospital, Army Medical UniversityChongqing
- RecruitingNeoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05765877
Age 18 years to Not stated (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingInduction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05766800
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingSavolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
- Phase
- Phase 1/Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT05777278
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2023-04
- Posted
- Registry
- NCT05786924
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Jinan, Shanghai, Suzhou
- RecruitingA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05789082
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Harbin, Shanghai
- RecruitingArmatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-01
- Posted
- Registry
- NCT05800223
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingNeoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
- Phase
- Phase 2
- Started
- 2023-04
- Posted
- Registry
- NCT05800340
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingAdjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
- Phase
- Phase 2
- Started
- 2023-04
- Posted
- Registry
- NCT05825443
Age 18 years to 80 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingImproving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma
- Phase
- Not given
- Started
- 2023-01
- Posted
- Registry
- NCT05830812
Age 20 years to 80 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingIntegrin αvβ6-targeted PET in Malignant Tumors
- Phase
- Not given
- Started
- 2023-01
- Posted
- Registry
- NCT05835570
Age 18 years to 85 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingExploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment
- Phase
- Not given
- Started
- 2023-05
- Posted
- Registry
- NCT05857800
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT05882058
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Hangzhou, Jinan, Nanchang, Shanghai
- RecruitingLK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2023-05
- Posted
- Registry
- NCT05886439
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05913089
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang
- RecruitingA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05920356
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT05924841
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- RecruitingA Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05940532
Age 18 years to 75 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingExploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2023-10
- Posted
- Registry
- NCT05965024
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingExploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT05965557
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT05978284
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingStudy of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT05987826
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT05989542
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingSmartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer
- Phase
- N/A
- Started
- 2023-12
- Posted
- Registry
- NCT05990946
Age 18 years to 75 years (registered criteria)
Led by Zhongshan City People's HospitalZhongshan
- RecruitingExploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
- Phase
- Not given
- Started
- 2023-08
- Posted
- Registry
- NCT05997719
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06010329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingTranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06023212
Age 10 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
- Phase
- Phase 3
- Started
- 2023-03
- Posted
- Registry
- NCT06031181
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAdjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
- Phase
- Phase 3
- Started
- 2023-03
- Posted
- Registry
- NCT06041776
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- RecruitingA Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-08
- Posted
- Registry
- NCT06043466
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingAlmonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
- Phase
- Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT06043973
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Shandong First Medical UniversityJinan
- RecruitingTransbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer
- Phase
- N/A
- Started
- 2023-10
- Posted
- Registry
- NCT06052098
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingEfficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
- Phase
- N/A
- Started
- 2023-05
- Posted
- Registry
- NCT06056115
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingSH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT06080776
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06095583
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou
- RecruitingThe Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06109558
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06119581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang
- RecruitingPhase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06123754
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingAdebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06125041
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Shandong First Medical UniversityJinan
- RecruitingA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-11
- Posted
- Registry
- NCT06131840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPhase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-04
- Posted
- Registry
- NCT06141226
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingRecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC
- Phase
- Not given
- Started
- 2023-11
- Posted
- Registry
- NCT06142058
Age 18 years to Not stated (registered criteria)
Led by Dapping HospitalChongqing
- RecruitingA Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06147570
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingCOVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
- Phase
- N/A
- Started
- 2023-12
- Posted
- Registry
- NCT06168032
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06170788
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou
- RecruitingTo Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06192849
Age 18 years to Not stated (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- RecruitingClinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06199895
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingRandomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06205927
Age 18 years to 80 years (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingExploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT06216782
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingEffects of Digital Therapeutic in Whole Process Management of Lung Cancer
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT06230445
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingDZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
- Phase
- Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT06276283
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingEfficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
- Phase
- N/A
- Started
- 2023-09
- Posted
- Registry
- NCT06286150
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingAssessment System of Sarcopenia in Lung Cancer Patients
- Phase
- Not given
- Started
- 2023-11
- Posted
- Registry
- NCT06327594
Age 40 years to 100 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingVebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
- Phase
- Phase 1/Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT06343064
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPredicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT06358222
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingDurvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT06371482
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingEfficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
- Phase
- Not given
- Started
- 2023-10
- Posted
- Registry
- NCT06399926
Age 18 years to Not stated (registered criteria)
Led by Xiangya HospitalChangsha
- RecruitingExploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
- Phase
- Not given
- Started
- 2023-08
- Posted
- Registry
- NCT06413212
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Recruitinga Single-arm, Single-center, Open Clinical Study
- Phase
- Not given
- Started
- 2023-07
- Posted
- Registry
- NCT06431100
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-04
- Posted
- Registry
- NCT06508307
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingA Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
- Phase
- N/A
- Started
- 2023-12
- Posted
- Registry
- NCT06512207
Age 60 years to Not stated; men only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingSurgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
- Phase
- Not given
- Started
- 2023-08
- Posted
- Registry
- NCT06534489
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingGlycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
- Phase
- Not given
- Started
- 2023-10
- Posted
- Registry
- NCT06730503
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingInvestigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
- Phase
- Not given
- Started
- 2023-02
- Posted
- Registry
- NCT06790797
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingOral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT07041320
Age 65 years to Not stated (registered criteria)
Led by Anhui Chest HospitalHefei
- RecruitingSmall Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2023-01
- Posted
- Registry
- NCT07070011
Age 45 years to 80 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingPatient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT07328945
Age 18 years to 80 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)
- Phase
- N/A
- Started
- 2022-02
- Posted
- Registry
- NCT03786003
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
- Phase
- N/A
- Started
- 2022-02
- Posted
- Registry
- NCT04527419
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingMediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
- Phase
- N/A
- Started
- 2022-05
- Posted
- Registry
- NCT04631770
Age not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingNeoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT04728724
Age 18 years to 75 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2022-03
- Posted
- Registry
- NCT04928846
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingPreoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2022-10
- Posted
- Registry
- NCT04973293
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05168566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Posted
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingAdjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05241028
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingFirst-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
- Phase
- Phase 1/Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT05271916
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingEfficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
- Phase
- Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05284539
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingMRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
- Phase
- Phase 2
- Started
- 2022-06
- Posted
- Registry
- NCT05286957
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05288205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
- RecruitingFurmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
- Phase
- Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05334277
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Foshan, Guangzhou, Hangzhou, Jiangmen, Nanchang, Shenyang, Urumqi, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingPatient's Whole Process Follow-up Management(HOPE-1)
- Phase
- Not given
- Started
- 2022-05
- Posted
- Registry
- NCT05339568
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Shandong First Medical UniversityJinan
- RecruitingEGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
- Phase
- Early phase 1
- Started
- 2022-05
- Posted
- Registry
- NCT05341492
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
- Phase
- Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05351788
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingMultiomics Tumor Evolution Model of NSCLC
- Phase
- Not given
- Started
- 2022-04
- Posted
- Registry
- NCT05352035
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingAK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-07
- Posted
- Registry
- NCT05377658
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingEfficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
- Phase
- N/A
- Started
- 2022-06
- Posted
- Registry
- NCT05378334
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingPhase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
- Phase
- Phase 3
- Started
- 2022-06
- Posted
- Registry
- NCT05382728
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Shanghai
- RecruitingAdjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT05457049
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFoshan, Guangzhou, Shantou, Zhongshan
- RecruitingA Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05482568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai
- RecruitingAn Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT05486650
Age 18 years to 75 years (registered criteria)
Led by Xinqiao Hospital, Army Medical UniversityChongqing
- RecruitingA Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
- Phase
- Phase 3
- Started
- 2022-12
- Posted
- Registry
- NCT05487391
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingJAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05490472
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changchun, Jinan
- RecruitingChina Lung Cancer Screening (CLUS) Study Version 3.0
- Phase
- N/A
- Started
- 2022-01
- Posted
- Registry
- NCT05494021
Age 45 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingA Real World Study of Ensartinib in Advanced ALK-positive NSCLC
- Phase
- Not given
- Started
- 2022-05
- Posted
- Registry
- NCT05498064
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05498428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Harbin, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai
- RecruitingNeoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
- Phase
- Phase 2
- Started
- 2022-02
- Posted
- Registry
- NCT05503667
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingAdjuvant Treatment Based on MRD for EGFR Mutant NSCLC
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05536505
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan
- RecruitingA Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05543330
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingImmune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
- Phase
- Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05584267
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingOsimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
- Phase
- Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT05686434
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingPhase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
- Phase
- Phase 1
- Started
- 2022-05
- Posted
- Registry
- NCT06128148
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingNeoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
- Phase
- Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT06241807
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingPulmonary Watershed Topographic Map Navigation for Lung Nodule Resection
- Phase
- N/A
- Started
- 2022-01
- Posted
- Registry
- NCT06404164
Age not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingStudy of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT06706713
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou
- RecruitingEpidemiology of Abdominal Aortic Aneurysm With Concomitant Primary Lung Cancer
- Phase
- Not given
- Started
- 2022-10
- Posted
- Registry
- NCT06775821
Age 20 years to 90 years (registered criteria)
Led by First Affiliated Hospital of Kunming Medical University; 1 listed hospital as study siteKunming
- RecruitingA Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT07231068
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Zhengzhou
- RecruitingResearch on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies.
- Phase
- Not given
- Started
- 2022-12
- Posted
- Registry
- NCT07370077
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingInduction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT07632365
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingCardiorespiratory Fitness After Lobectomy Versus Sublobar Resection
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT07841249
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingThe Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.
- Phase
- Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT04777084
Age 18 years to 75 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingEfficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy
- Phase
- Phase 3
- Started
- 2021-04
- Posted
- Registry
- NCT04829708
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingEngineered TILs/CAR-TILs to Treat Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2021-01
- Posted
- Registry
- NCT04842812
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingTo Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
- Phase
- Phase 3
- Started
- 2021-06
- Posted
- Registry
- NCT04853342
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
- RecruitingBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase
- Phase 1
- Started
- 2021-07
- Posted
- Registry
- NCT04886804
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
- RecruitingA Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules
- Phase
- Phase 2
- Started
- 2021-01
- Posted
- Registry
- NCT04905056
Age 18 years to 85 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Phase
- Phase 1
- Started
- 2021-08
- Posted
- Registry
- NCT04913285
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHarbin, Linyi, Shanghai
- RecruitingStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT04930432
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingComparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field
- Phase
- N/A
- Started
- 2021-07
- Posted
- Registry
- NCT04944563
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2021-03
- Posted
- Registry
- NCT04951635
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan
- RecruitingIntratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2021-03
- Posted
- Registry
- NCT04952272
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingMRD Monitoring in Lung Cancer After Resection
- Phase
- Not given
- Started
- 2021-09
- Posted
- Registry
- NCT04976296
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingEarly Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
- Phase
- Phase 3
- Started
- 2021-06
- Posted
- Registry
- NCT04980716
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT04996121
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingNeoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
- Phase
- Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT05011487
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05014464
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05024214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Shanghai, Shenyang, Taiyuan, Tianjin, Zhengzhou, Zhuhai
- RecruitingEfficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
- Phase
- Phase 2
- Started
- 2021-03
- Posted
- Registry
- NCT05053802
Age 18 years to 79 years (registered criteria)
Led by Shanghai Pulmonary Hospital; 5 listed hospitals as study sitesShanghai
- RecruitingEfficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
- Phase
- Phase 3
- Started
- 2021-10
- Posted
- Registry
- NCT05055908
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingChemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
- Phase
- Not given
- Started
- 2021-10
- Posted
- Registry
- NCT05059951
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 1/Phase 2
- Started
- 2021-10
- Posted
- Registry
- NCT05099172
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Taizhou
- RecruitingA Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2021-10
- Posted
- Registry
- NCT05104788
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingRadiotherapy or Observation of Liver Metastases in Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2021-04
- Posted
- Registry
- NCT05150145
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang
- RecruitingTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05187338
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingPhase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
- Phase
- N/A
- Started
- 2021-01
- Posted
- Registry
- NCT05552846
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingAssessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)
- Phase
- N/A
- Started
- 2021-11
- Posted
- Registry
- NCT05559645
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingExploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
- Phase
- Not given
- Started
- 2021-09
- Posted
- Registry
- NCT05598528
Age 18 years to Not stated (registered criteria)
Led by Second Xiangya HospitalChangsha
- RecruitingPhase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT05751018
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingNeuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
- Phase
- Not given
- Started
- 2021-01
- Posted
- Registry
- NCT06369181
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingReal World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
- Phase
- Phase 2
- Started
- 2021-05
- Posted
- Registry
- NCT07198217
Age 18 years to 75 years (registered criteria)
Led by Zibo Municipal HospitalZibo
- RecruitingIntraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
- Phase
- N/A
- Started
- 2020-04
- Posted
- Registry
- NCT04209218
Age 50 years to 90 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
- Phase
- Phase 3
- Started
- 2020-07
- Posted
- Registry
- NCT04316364
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Zhengzhou
- RecruitingAnlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2020-03
- Posted
- Registry
- NCT04322617
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
- Phase
- Phase 2
- Started
- 2020-04
- Posted
- Registry
- NCT04322890
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingSurvival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
- Phase
- Not given
- Started
- 2020-03
- Posted
- Registry
- NCT04324164
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingPD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
- Phase
- Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04539977
Age 18 years to 75 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Phase
- Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04557449
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2020-11
- Posted
- Registry
- NCT04606446
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an
- RecruitingPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Phase
- Phase 2/Phase 3
- Started
- 2020-12
- Posted
- Registry
- NCT04613596
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingThe Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
- Phase
- Not given
- Started
- 2020-06
- Posted
- Registry
- NCT05477979
Age 18 years to Not stated (registered criteria)
Led by Second Xiangya HospitalChangsha
- RecruitingNeoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
- Phase
- Phase 2
- Started
- 2019-03
- Posted
- Registry
- NCT03872661
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAPG-2449 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2019-05
- Posted
- Registry
- NCT03917043
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Wuhan
- RecruitingAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-07
- Posted
- Registry
- NCT04270591
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou
- RecruitingThe Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
- Phase
- Not given
- Started
- 2019-05
- Posted
- Registry
- NCT04286841
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingLung Surgery With Enhanced Recovery VS. Lung Surgery Without Enhanced Recovery
- Phase
- N/A
- Started
- 2019-10
- Posted
- Registry
- NCT04451473
Age 18 years to 85 years (registered criteria)
Led by Second Hospital of Shandong UniversityJinan
- RecruitingSegmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
- Phase
- N/A
- Started
- 2019-10
- Posted
- Registry
- NCT04937283
Age 20 years to 79 years (registered criteria)
Led by Shanghai Pulmonary Hospital; 8 listed hospitals as study sitesHangzhou, Hefei, Nantong, Ningbo, Shanghai, Xuzhou
- RecruitingStudy of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
- Phase
- Early phase 1
- Started
- 2019-09
- Posted
- Registry
- NCT05060796
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingMolecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT05701787
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingComparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
- Phase
- Not given
- Started
- 2019-08
- Posted
- Registry
- NCT05838053
Age 20 years to 79 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingCharacteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
- Phase
- Not given
- Started
- 2019-11
- Posted
- Registry
- NCT06255197
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingLcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
- Phase
- Not given
- Started
- 2019-06
- Posted
- Registry
- NCT06778512
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingDevelopment and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT06950697
Age 18 years to Not stated (registered criteria)
Led by Beijing Chao-Yang Hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou
- RecruitingThe Shengjing Lung Cancer Cohort (SJ-LCC) Study on Risk Factors for Disease Development and Progression
- Phase
- Not given
- Started
- 2019-02
- Posted
- Registry
- NCT07779005
Age 18 years to 75 years (registered criteria)
Led by Shengjing Hospital of China Medical UniversityShenyang
- RecruitingA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Phase
- Phase 1
- Started
- 2018-04
- Posted
- Registry
- NCT03460977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Nanjing, Wenzhou
- RecruitingSurvival Outcomes of Lung Cancer
- Phase
- Not given
- Started
- 2018-08
- Posted
- Registry
- NCT03647098
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2018-11
- Posted
- Registry
- NCT03755739
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingEvaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
- Phase
- N/A
- Started
- 2018-11
- Posted
- Registry
- NCT03769129
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingTCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2018-12
- Posted
- Registry
- NCT03778814
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingAnalysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
- Phase
- Not given
- Started
- 2018-01
- Posted
- Registry
- NCT05636605
Age 18 years to 80 years (registered criteria)
Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou
- RecruitingiCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
- Phase
- Not given
- Started
- 2017-07
- Posted
- Registry
- NCT03192501
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingStudy of High Efficient Killing Cell Therapy for Advanced NSCLC
- Phase
- Phase 1
- Started
- 2017-09
- Posted
- Registry
- NCT03193567
Age 18 years to 70 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingGPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
- Phase
- Phase 1
- Started
- 2017-07
- Posted
- Registry
- NCT03198052
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou
- RecruitingGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- Phase
- Phase 1
- Started
- 2017-07
- Posted
- Registry
- NCT03198546
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou
- RecruitingSurgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
- Phase
- Phase 2
- Started
- 2017-09
- Posted
- Registry
- NCT03351842
Age 19 years to 70 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- RecruitingStereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
- Phase
- Phase 2
- Started
- 2017-08
- Posted
- Registry
- NCT03392233
Age 18 years to 85 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingIntegrative Analysis of Large-cell Lung Cancer
- Phase
- Not given
- Started
- 2016-01
- Posted
- Registry
- NCT02917369
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai
- RecruitingAnalysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2016-07
- Posted
- Registry
- NCT04977791
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingMolecular Analysis and Treatment Options of SCLC
- Phase
- Not given
- Started
- 2016-01
- Posted
- Registry
- NCT05945745
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingAssociation of Psychological Distress in Patients With Lung Cancer
- Phase
- Not given
- Started
- 2016-01
- Posted
- Registry
- NCT06218901
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- RecruitingNon-risk Based Lang Cancer Screening With a One-off LDCT
- Phase
- N/A
- Started
- 2015-12
- Posted
- Registry
- NCT04938804
Age 40 years to 74 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
- Phase
- Not given
- Started
- 2012-09
- Posted
- Registry
- NCT01994057
Age 18 years to 85 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2008-01
- Posted
- Registry
- NCT02889666
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai
- Not yet recruitingA Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2027-12
- Posted
- Registry
- NCT05745740
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingClinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2027-01
- Posted
- Registry
- NCT07928882
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingComparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung Cancer.
- Phase
- Phase 2
- Started
- 2027-01
- Posted
- Registry
- NCT07944313
Age 60 years to 90 years (registered criteria)
Led by Quanzhou First Hospital, Fujian Medical UniversityQuanzhou
- Not yet recruitingEfficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT06706219
Age 18 years to 70 years (registered criteria)
Led by Hunan Cancer Hospital; 1 listed hospital as study siteChangsha
- Not yet recruitingSERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT06772363
Age 18 years to Not stated (registered criteria)
Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou
- Not yet recruitingSERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT06775015
Age 18 years to Not stated (registered criteria)
Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou
- Not yet recruitingSERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT06775587
Age 18 years to Not stated (registered criteria)
Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou
- Not yet recruitingLimertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07001995
Age 18 years to 80 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- Not yet recruitingA Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07014878
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- Not yet recruitingSafety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07258147
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingGolidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07303881
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingA Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07307443
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingNK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07318636
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingA Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07318883
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingA Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07338396
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Guangzhou
- Not yet recruitingSacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07343479
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingLidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07347977
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Ningbo UniversityNingbo
- Not yet recruitingStudy on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions
- Phase
- N/A
- Started
- 2026-02
- Posted
- Registry
- NCT07352176
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingExploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07357532
Age 18 years to 80 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingClinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
- Phase
- Phase 4
- Started
- 2026-01
- Posted
- Registry
- NCT07358520
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Xuzhou
- Not yet recruitingToripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07358689
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingPhase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07360132
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingFurmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07365410
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruiting18F-FAPI PET in Lung Cancer
- Phase
- Not given
- Started
- 2026-02
- Posted
- Registry
- NCT07370805
Age 20 years to 85 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
- Phase
- Not given
- Started
- 2026-02
- Posted
- Registry
- NCT07375979
Age 40 years to 74 years (registered criteria)
Led by Shanghai Pulmonary Hospital; 5 listed hospitals as study sitesChangchun, Kunming, Shanghai, Shenyang, Zhengzhou
- Not yet recruitingIparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07379398
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingAdebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07381543
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingPhase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07383116
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingNon-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07395375
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingAdebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07398560
Age 18 years to 99 years (registered criteria)
Led by Third Affiliated Hospital of Harbin Medical UniversityHarbin
- Not yet recruitingIBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07402070
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingTubeless Strategy for Enhanced Recovery After Sublobar Resection
- Phase
- N/A
- Started
- 2026-02
- Posted
- Registry
- NCT07409129
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07410611
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingLimertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07413952
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingA Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07414927
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingVideo Double-Lumen Tube for Secondary Pulmonary Resection
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07467005
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHangzhou
- Not yet recruitingA Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
- Phase
- Phase 4
- Started
- 2026-04
- Posted
- Registry
- NCT07469488
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingA Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
- Phase
- Phase 4
- Started
- 2026-05
- Posted
- Registry
- NCT07485920
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Qingdao University; 1 listed hospital as study siteQingdao, Yantai
- Not yet recruitingOsimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07486648
Age 18 years to Not stated (registered criteria)
Led by Shanxi Cancer Hospital; 1 listed hospital as study siteBeijing, Taiyuan
- Not yet recruitingStudy on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07493980
Age 18 years to 80 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingSacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07501169
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingCombining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07517640
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingIparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07538193
Age 18 years to Not stated (registered criteria)
Led by Tangdu HospitalXi'an
- Not yet recruitingA Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07538973
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesQingdao, Shanghai
- Not yet recruitingEfficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07545213
Age 18 years to Not stated (registered criteria)
Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou
- Not yet recruitingA Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07550842
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangzhou, Harbin, Shanghai, Shenyang, Taizhou, Wuhan, Zhengzhou
- Not yet recruitingZorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07551414
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingGFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07554859
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingPhase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07558200
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingAdebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07560358
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingTislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07561983
Age 18 years to 80 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- Not yet recruitingA Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07583316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingA Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07583771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruiting5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07589101
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingPreoperative Decision-Making in Patients With Pulmonary Nodules Suspected of Lung Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07590596
Age 18 years to Not stated (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- Not yet recruitingApplication of Electromagnetic Navigation System in Pulmonary Nodule Localization
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07595120
Age 18 years to 80 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingAnalysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07596524
Age 1 year to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTaiyuan
- Not yet recruitingA Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07601048
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingA Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(Phase II Study Ongoing)
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07609251
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingSelective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07617389
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingIntermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07618793
Age 18 years to 75 years (registered criteria)
Led by Xuanwu HospitalBeijing
- Not yet recruitingA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07623642
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin
- Not yet recruitingStudy of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07624214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingBecotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07627321
Age 18 years to 75 years (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- Not yet recruitingDeep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT
- Phase
- Not given
- Started
- 2026-06
- Posted
- Registry
- NCT07647692
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingA Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07661173
Age 18 years to Not stated (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- Not yet recruitingA Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
- Phase
- Phase 1
- Started
- 2026-10
- Posted
- Registry
- NCT07663630
Age 18 years to Not stated (registered criteria)
Led by The University of Hong Kong–Shenzhen HospitalShenzhen
- Not yet recruitingPhase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07670715
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingA Clinical Study GK01 Cell Injection in Subjects With Advanced Lung Cancer
- Phase
- Early phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07673419
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingRucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
- Phase
- Phase 4
- Started
- 2026-07
- Posted
- Registry
- NCT07674368
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- Not yet recruitingManagement Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07674524
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07686185
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical UniversityNanning
- Not yet recruitingSegmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07698990
Age 18 years to 80 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingHSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07699757
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingThe Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07704645
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Phase 2 Study of ABSK043 Combined With Osimertinib
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07710612
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Taiyuan, Wuhan
- Not yet recruitingJS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC
- Phase
- N/A
- Started
- 2026-07
- Posted
- Registry
- NCT07714304
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai
- Not yet recruitingRehabilitation With Wearable Monitors for Post-Lung Cancer Surgery
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07733492
Age 18 years to 85 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingMulti-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer Patients
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07742800
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingSafety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07745790
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingMicrobiota in Neoadjuvant Chemoimmunotherapy for NSCLC
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07752589
Age 18 years to 80 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingA Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07771764
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- Not yet recruitingSpatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07775040
Age 18 years to 75 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- Not yet recruitingThiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07778940
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingThe Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07780578
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingDigital Rehabilitation With Wearable Monitors for Sequential Lung Cancer Resection
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07797075
Age 18 years to 85 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingNeoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07807722
Age 18 years to 70 years (registered criteria)
Led by Hubei Cancer HospitalWuhan
- Not yet recruitingSafety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors
- Phase
- Phase 1
- Started
- 2026-09
- Posted
- Registry
- NCT07815951
Age 18 years to 75 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Not yet recruitingPaclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07819591
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingVideo-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS Alone for Multiple Primary Lung Cancer
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07819669
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shenzhen
- Not yet recruitingA Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07827261
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingAI-Assisted Chest CT Interpretation Across the Lung Cancer Care Continuum
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07829640
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Not yet recruiting5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies
- Phase
- N/A
- Started
- 2026-11
- Posted
- Registry
- NCT07830095
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingA Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07831863
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07833202
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanchang
- Not yet recruitingLocal Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07842471
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingPhase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance
- Phase
- Phase 1
- Started
- 2026-10
- Posted
- Registry
- NCT07842887
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingQuad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07845916
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingVideo-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07849400
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Jiaxing
- Not yet recruitingAn Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07849712
Age 75 days to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingA Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07865910
Age 18 days to 75 days (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesAnyang, Beijing, Chongqing, Guangzhou, Jinan, Nanning, Qingdao, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou, Zunyi
- Not yet recruitingMRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
- Phase
- N/A
- Started
- 2026-11
- Posted
- Registry
- NCT07873086
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingPhase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07874282
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingProspective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07874464
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingIntestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07875465
Age 18 years to Not stated (registered criteria)
Led by Hangzhou Cancer HospitalHangzhou
- Not yet recruitingPhase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
- Phase
- Phase 1
- Started
- 2026-10
- Posted
- Registry
- NCT07875920
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingFirmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07878871
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- Not yet recruitingDiagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07882628
Age 18 years to 75 years (registered criteria)
Led by Beijing Chao-Yang Hospital; 4 listed hospitals as study sitesBeijing, Changsha
- Not yet recruitingUnion-LC-MPE Cohort:A Multicenter Cohort Study on Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cance
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07882758
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingMRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07885709
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingPulsed Field Ablation for the Treatment of Malignant Lung Tumors
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07889297
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingAdebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07890636
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingSHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study
- Phase
- Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07895992
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingA Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-12
- Posted
- Registry
- NCT07896005
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai
- Not yet recruitingASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07897188
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingLow-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07909863
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingStudy of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-11
- Posted
- Registry
- NCT07912268
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Fuzhou, Harbin, Nanchang, Shanghai
- Not yet recruitingClinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07936578
Age 18 years to 75 years (registered criteria)
Led by Affiliated Cancer Hospital of Guizhou Medical UniversityGuiyang
- Not yet recruitingNeoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06688656
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingMRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
- Phase
- Early phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06735508
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingThe Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06739421
Age 18 years to 90 years (registered criteria)
Led by China-Japan Friendship HospitalBeijing
- Not yet recruitingThe Accuracy of Targeted Lymph Node Dissection of Non-small Cell Lung Cancer Patients According to Predictive Models
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06768853
Age 18 years to 70 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Not yet recruitingAdjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06780839
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingAdebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06784206
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingEfficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical Study
- Phase
- Phase 4
- Started
- 2025-02
- Posted
- Registry
- NCT06785584
Age 18 years to Not stated (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingReal-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06786208
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingA Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06786312
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer Hospital; 3 listed hospitals as study sitesFuzhou, Xiamen
- Not yet recruitingThe Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung Resection
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06789276
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingNanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06793228
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer Hospital; 1 listed hospital as study siteLuoyang, Zhengzhou
- Not yet recruitingIrinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06820762
Age 18 years to 75 years (registered criteria)
Led by Second Hospital of Dalian Medical University; 1 listed hospital as study siteDalian, Shenyang
- Not yet recruitingClinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-05
- Posted
- Registry
- NCT06828757
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- Not yet recruitingNeoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06837948
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingXingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06848426
Age 18 years to 75 years (registered criteria)
Led by Jiangxi Provincial People's HospitalNanchang
- Not yet recruitingTislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06851819
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingStudy of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06885840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingBenmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
- Phase
- Phase 4
- Started
- 2025-04
- Posted
- Registry
- NCT06931145
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingProspective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
- Phase
- Phase 4
- Started
- 2025-04
- Posted
- Registry
- NCT06951841
Age 18 years to Not stated (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- Not yet recruitingClinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06961188
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingNano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
- Phase
- Phase 3
- Started
- 2025-05
- Posted
- Registry
- NCT06961201
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- Not yet recruitingA Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06963502
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou
- Not yet recruitingNAD+ Supplement(NMN)With Radioimmunotherapy in Advanced NSCLC
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06966583
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingA Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06977828
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingClinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT06994078
Age 18 years to 65 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingNeoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06998719
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingEfficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07004712
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingAI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Leptomeningeal Metastasis: A Dual-Center Study
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07005791
Age 18 years to 75 years (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- Not yet recruitingA Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07031154
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- Not yet recruitingEnteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT07035444
Age 18 years to Not stated (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- Not yet recruitingEfficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07035860
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingA Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07036185
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07038460
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Guangzhou, Hangzhou
- Not yet recruitingSerplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07064876
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingA Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07083375
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingA Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07086326
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai, Xi'an
- Not yet recruitingEfficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC
- Phase
- Not given
- Started
- 2025-08
- Posted
- Registry
- NCT07093762
Age 18 years to Not stated (registered criteria)
Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou
- Not yet recruitingToripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07097948
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingA Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07101627
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary Hospital; 1 listed hospital as study siteNanjing, Shanghai
- Not yet recruitingA Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07103408
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingIparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07129161
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Xi'an
- Not yet recruitingNovel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07135297
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest Hospital; 4 listed hospitals as study sitesBeijing, Nanjing, Ningbo, Shanghai, Zhengzhou
- Not yet recruitingNebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07150416
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingVebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07156604
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingAK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07158840
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingSegmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07169903
Age 20 years to 79 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingOpen-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07172412
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingAnalysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07179445
Age 18 years to 100 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingHigh-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07182708
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingPostbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer
- Phase
- N/A
- Started
- 2025-11
- Posted
- Registry
- NCT07185308
Age 18 years to Not stated (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- Not yet recruitingA Real-World Study of IBI351 for KRAS G12C+ NSCLC in China
- Phase
- Not given
- Started
- 2025-10
- Posted
- Registry
- NCT07198620
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingReal-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
- Phase
- Not given
- Started
- 2025-10
- Posted
- Registry
- NCT07199010
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingAdebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07200154
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingA Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07200947
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingPenfluridol for Relapsed/Refractory Small Cell Cancers
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07206563
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingPhase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07242274
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingSac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07244926
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingThe Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07277088
Age 18 years to 80 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingStereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07286942
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Cancer HospitalNanjing
- Not yet recruitingPrediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07287904
Age 18 years to 80 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingAdebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06236997
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer Hospital; 1 listed hospital as study siteWuhan, Zhengzhou
- Not yet recruitingA Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06254599
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingMyeloprotection With Trilaciclib in Pan-cancer Population
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06297811
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingSafety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06332950
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingClinical Study of 18F-Alfatide Injection PET/CT
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06416852
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingA Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
- Phase
- N/A
- Started
- 2024-06
- Posted
- Registry
- NCT06422637
Age 40 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingEfficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
- Phase
- N/A
- Started
- 2024-06
- Posted
- Registry
- NCT06453889
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingTrametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06456138
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingNeoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06475755
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- Not yet recruitingA Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06524518
Age 18 years to 80 years (registered criteria)
Led by Xuanwu HospitalBeijing
- Not yet recruitingCryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer
- Phase
- N/A
- Started
- 2024-09
- Posted
- Registry
- NCT06580665
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesNanchang, Shanghai, Wenzhou, Wuhan
- Not yet recruitingClinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06585059
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingA Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06585644
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingA Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06594874
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingBronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06604351
Age 18 years to 80 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- Not yet recruitingTP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
- Phase
- Early phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06619886
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- Not yet recruitingEfficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06620822
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingThird-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06634667
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- Not yet recruitingA Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06690671
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Not yet recruitingStudy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-12
- Posted
- Registry
- NCT06704620
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingMinimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT06709274
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Chengdu, Foshan, Guangzhou, Nanjing, Nantong, Shenzhen, Wuhan
- Not yet recruitingA Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06724263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingAumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06752408
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingThe Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-08
- Posted
- Registry
- NCT05496166
Age 18 years to 70 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingYK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05767892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingSingle Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
- Phase
- N/A
- Started
- 2023-06
- Posted
- Registry
- NCT05802654
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- Not yet recruitingctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy
- Phase
- Not given
- Started
- 2023-04
- Posted
- Registry
- NCT05822284
Age 18 years to 75 years (registered criteria)
Led by Second Xiangya HospitalChangsha
- Not yet recruitingA Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-07
- Posted
- Registry
- NCT05940116
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05990127
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
- Not yet recruitingStudy of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
- Phase
- Phase 1
- Started
- 2023-09
- Posted
- Registry
- NCT06015568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBengbu, Changsha, Shanghai
- Not yet recruitingWedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06102161
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingPerioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06109402
Age 18 years to Not stated (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Not yet recruitingA Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06142617
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingNeoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
- Phase
- Phase 2
- Started
- 2022-01
- Posted
- Registry
- NCT05132985
Age 18 years to 75 years (registered criteria)
Led by Liaoning Cancer Hospital & InstituteShenyang
- Not yet recruitingThe ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer
- Phase
- N/A
- Started
- 2022-06
- Posted
- Registry
- NCT05411809
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- Not yet recruitingPenpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
- Phase
- Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT04846634
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteNanchang, Tianjin
- Enrolling by invitationComparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07373899
Age not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationBronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07738367
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- Enrolling by invitationEvaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07920822
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Enrolling by invitationEfficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT06883136
Age 60 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Shandong First Medical UniversityJinan
- Enrolling by invitationThe Effect of Esketamine Combined With Dexmedetomidine on Postoperative Recovery Quality in Patients Undergoing Thoracoscopic Surgery
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT07125573
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Kunming Medical UniversityKunming
- Enrolling by invitationRetrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07373951
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Enrolling by invitationSpontaneous Breathing Mode: A Risk for Hypoxemia During OLV?
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07494006
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Enrolling by invitationSingle-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07916129
Age 18 years to 85 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Enrolling by invitationthe Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06370416
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Enrolling by invitationPerioperative Treatment Outcomes of Early NSCLC
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06610240
Age not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Enrolling by invitationEvaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06690216
Age 18 years to Not stated (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- Enrolling by invitationINK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer
- Phase
- Early phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06747832
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWeifang
- Enrolling by invitationAdjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06773156
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Nanchang UniversityNanchang
- Enrolling by invitationLORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT06876675
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- Enrolling by invitationReal-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06962449
Age not stated (registered criteria)
Led by Shanghai Chest HospitalShanghai
- Enrolling by invitation⁶⁸Ga-DPA in the Lung Cancer Diagnosis
- Phase
- Early phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT07023068
Age 18 years to 85 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Enrolling by invitationThe Effect of Semi-recumbent Position on Hypoxemia After Lung Segment/Lobe Surgery
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT07060625
Age 18 years to 85 years (registered criteria)
Led by Shanghai Pulmonary HospitalShanghai
- Enrolling by invitationApplication of Generative Artificial Intelligence in Perioperative Personalized Rehabilitation for Older Adults With Lung Cancer
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT07915193
Age 65 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Enrolling by invitationComparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study
- Phase
- N/A
- Started
- 2023-01
- Posted
- Registry
- NCT06028412
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- Enrolling by invitationEfficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06281964
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Enrolling by invitationChemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06816966
Age 18 years to Not stated (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Enrolling by invitationPersonalized SBRT in Early-Stage Peripheral NSCLC
- Phase
- Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT07167459
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Enrolling by invitationEfficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT04762459
Age 18 years to 130 years (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- Enrolling by invitationThe Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
- Phase
- Not given
- Started
- 2021-01
- Posted
- Registry
- NCT06647836
Age 18 years to 80 years (registered criteria)
Led by Union HospitalWuhan
- Enrolling by invitationPlasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
- Phase
- Not given
- Started
- 2021-01
- Posted
- Registry
- NCT06730477
Age 18 years to 80 years (registered criteria)
Led by Union HospitalWuhan
- Enrolling by invitationFHND9041 Versus Afatinib for Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT06759857
Age 18 months to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 18 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.